Aptevo Therapeutics – huge potential with high risk
I bought Aptevo Therapeutics (APVO) to the spin-off portfolio at $2.40. Note: This is a biotechnology company with high risk profile. * * * Six months ago, I bought shares of Nuvectra Corporation (NVTR) –…